Britain and America have secured a major trade agreement that will maintain zero levies on UK medicine exports being sold in the US market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to increase spending on pharmaceuticals through the public health system. This commitment secures that import taxes on these vital products will stay at zero for a duration of three years.
This development is in response to recent warnings to significantly raise duties on patented drug products, with figures discussed as high as one hundred percent.
"This agreement with the UK bolsters the global environment for new treatments and brings much-needed equity to American-British pharmaceutical trade," a release noted.
Trade Impact
Medicines constitute one of the UK's largest exports to the US, which is easily the primary buyer for large UK drugmakers.
Statistics reveal that in the 12 months prior to the third quarter, the UK sold pharmaceutical products worth £11.1bn to the US. This figure represented nearly one-fifth of British export trade in that timeframe.
"This deal protects jobs, stimulates capital expenditure and paves the way for the UK to emerge as a international leader for medical research," a government official commented.
Specific UK Commitments
The pact involves several key changes from the British government:
- Price Threshold Increase: The UK will increase the affordability limit at which it considers new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a goal to increase overall health service expenditure on medicines from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage manufacturers must refund to the NHS to stay within budget will be limited at 15%. Last year, refunds topped twenty percent.
Recent Tensions
The pact follows a ongoing dispute between the pharmaceutical industry and the ministers over spending levels and NHS adoption.
The disagreement were heightened by arguments that American patients were charged several times more for the same drugs than people in the UK and Europe.
In recent months, several major manufacturing plans in the UK have been halted or scrapped, while major funding commitments have been pledged toward American operations.
A senior figure acknowledged that the NHS must increase expenditure on treatments, noting that its spending on drugs had shrunk as a share of its resources over the previous ten-year period.
